References
- Antithrombotic Trialists’ (ATT) Collaboration . Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 373(9678), 1849–1860 (2009).
- Bhatt DL , FoxKA, HackeWet al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med., 354(16), 1706–1717 (2006).
- Warfarin Antiplatelet Vascular Evaluation Trial Investigators . Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N. Engl. J. Med., 357(3), 217–227 (2007).
- Mauri L , KereiakesDJ, YehRWet al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N. Engl. J. Med., 371(23), 2155–2166 (2014).
- Bonaca MP , BhattDL, CohenMet al. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl. J. Med., 372(19), 1791–1800 (2015).
- Eikelboom JW , ConnollySJ, BoschJet al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N. Engl. J. Med., 377(14), 1319–1330 (2017).
- Steg PG , BhattDL, SimonTet al. Ticagrelor in patients with stable coronary disease and diabetes. N. Engl. J. Med., 381(14), 1309–1320 (2019).
- Fanaroff AC , HasselbladV, RoeMTet al. Antithrombotic agents for secondary prevention after acute coronary syndromes: a systematic review and network meta-analysis. Int. J. Cardiol., 241, 87–96 (2017).
- Mauri L , ElmariahS, YehRWet al. Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur. Heart J., 37(4), 378–385 (2016).